Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
LENZ Therapeutics, Inc. - Common Stock
(NQ:
LENZ
)
16.12
-0.40 (-2.42%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about LENZ Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Today 12:45 EST
From
Pomerantz LLP
Via
GlobeNewswire
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
December 01, 2025
Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-U.S. regulatory submission for VIZZ
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics to Present at Upcoming Investor Conferences
November 25, 2025
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 05, 2025
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025
October 29, 2025
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
September 30, 2025
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
August 25, 2025
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
July 31, 2025
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
July 30, 2025
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia
July 28, 2025
Submission of NDA for LNZ100 in China by CORXEL Pharmaceuticals results in achievement of first milestone due to LENZ under the Development and Commercialization Agreement
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
July 07, 2025
Exclusive agreement includes over $70 million in upfront and milestone payments to LENZ in addition to double-digit royalties on net sales
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics to Present at Upcoming Investor Conferences
May 27, 2025
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
May 09, 2025
Exclusive agreement includes up to $125 million in upfront and milestone payments to LENZ together with double-digit royalties on future net sales
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
May 07, 2025
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference
May 06, 2025
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025
April 30, 2025
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
April 01, 2025
Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors
From
Climb Bio, Inc.
Via
GlobeNewswire
LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
March 19, 2025
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025
March 11, 2025
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics to Host Commercial Day on April 15, 2025
March 03, 2025
Event to highlight the commercialization strategy and progress towards the potential approval of LNZ100 for the treatment of presbyopia
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics to Participate in Upcoming Investor Conferences
February 24, 2025
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics to Participate in Upcoming Investor Conferences
November 12, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Reports Third Quarter 2024 Financial Results
November 06, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024
October 30, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100
October 27, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
October 21, 2024
FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
September 30, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics to Participate in Upcoming Investor Conferences
August 27, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Reports Second Quarter 2024 Financial Results
August 14, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia
August 12, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
